Mesothelin (MSLN) antibody

Antigen: Mesothelin (MSLN)

Synonyms: MPF, SMR, CAK1, MSLN

Clonality: Monoclonal

Host: Rabbit

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB)

Certificates: ISO 9001:2008

Catalog no.: ABIN650040

Additional Information

Alternative name: Mesothelin

Gene ID: 2641

UniProt: Q13421

Characteristics: Rabbit Monoclonal IgG

Specificity: A synthetic peptide corresponding to residues near the C-terminus of human Mesothelin was used as an immunogen. This antibody detects full-length Mesothelin precursor (69 kDa) and C-terminal cleaved form of Mesothelin (40 kDa).

Molecular Weight: 69/40 kDA

Comments:

Background: Mesothelin is a tumor differentiation antigen that is present on the surface of normal mesothelial cells lining the pleura, peritoneum and pericardium. It is over expressed in many human tumors, including malignant mesothelioma and ovarian, pancreatic and lung adenocarcinomas (1). The normal biologic function of mesothelin is unknown but recent studies have shown that it forms a strong and specific complex with MUC16, a binding which has been suggested to be the basis of ovarian cancer metastasis (2). Initially, mesothelin is produced as a polypeptide with a hydrophobic tail which is removed and replaced by phosphatidylinositol. After glycosylation at the one or more of its four putative N-linked glycosylation sites, it is cleaved by a protease to yield the 40 kDa fragment (or doublet) (3). Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer (4).

Application Details

Application Notes: The suggested dilution is: WB: ~~ 1:1000~10000

Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.

Storage: Mesothelin Antibody can be stored at -20°C for up to 12 months from time of receipt.

Research Area: Cell Signaling, Protein Modifications, Cell Structure

Restrictions: For Research Use only

Publications

Product: Chang, Pastan: "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, Issue 1, pp. 136-40, 1996 (PubMed).

Hassan, Ho: "Mesothelin targeted cancer immunotherapy." in: European journal of cancer (Oxford, England : 1990), Vol. 44, Issue 1, pp. 46-53, 2007 (PubMed).

"The universal protein resource (UniProt)." in: Nucleic acids research, Vol. 36, Issue Database issue, pp. D190-5, 2008 (PubMed).

Sathyanarayana, Hahn, Patankar et al.: "Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats." in: BMC structural biology, Vol. 9, pp. 1, 2009 (PubMed).